To study the effect of anti-SLAMF6 on tumor progression we use the aggressive transplantable murine CLL clone TCL1-192 and the B cell lymphoma LMP2A/λMyc [33–35] into SCID or Rag1−/− mice, respectively. Here, MYCL is linked to B-cell non-Hodgkin lymphoma.